Upcoming Earnings: Q2 '26
Estimated EPS
$0.00
Estimated Rev
$42.19M
$HRTX Q1 '26 Earnings Results & Recap Heron Therapeutics reported Q1 2026 net product sales of $34.7M, yielding an $8.1M net loss or $0.04 per share; acute care sales rose $3.3M, while oncology sales decreased -$7.5M.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.00 | -- | -- | N/A |
Q1 '26 | -$0.02 | -$0.04 | -71.43% | MISSED |
Q4 '25 | -$0.02 | -$0.02 | -- | EXPECTED |
Q3 '25 | -$0.01 | -$0.10 | -566.67% | MISSED |
Q2 '25 | -$0.01 | -$0.02 | -100.00% | MISSED |